Skip to content
TrialMatch
Sign up
Recruiting

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.

Condition
Carcinoma, Endometrioid, Fertility Preservation
Tested
Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Sponsor
Peking University People's Hospital

Who can join

Age
Up to 45 years
Sex
Female only
Healthy volunteers
Not accepted

Inclusion 9

  • Maximum age: 45 years
  • Eligible sex: Female
  • Study condition: Carcinoma, Endometrioid, Fertility Preservation
  • Endometrioid adenocarcinoma G2, diagnosis by pathological.
  • The lesion is limited to the endometrium.
  • FIGO (2009) staging is IA.
  • Age less than 45.
  • Strongly request to preserve fertility.
  • Sign informed consent.

Exclusion 6

  • The tumor has invaded the muscle layer.
  • FIGO (2009) stage IB or higher.
  • Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer
  • There are malignant tumors in other systems.
  • Have contraindications for conservative treatment or drug use.
  • Have been judged by the researcher to be unsuitable for childbearing.

Where

1 site, 1 recruiting

Peking University People's Hospital

Beijing, Beijing Municipality, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.